52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)

作者：A. Vogel, S. Boeck, O. Waidmann, Michel Bitzer, P. Wenzel, S. Belle, C. Springfeld, K. Schulze, A. Weinmann, U. Lindig, C. Trautwein, T. Dechow, F. Lammert, R. Plentz, C-H. Koehne, V. Kunzmann, M. Maenz, M.M. Kirstein, A. Saborowski · 发表于：Annals of Oncology · 年份：2022 · DOI：10.1016/j.annonc.2022.07.080 · 被引用次数：9 · 研究领域：Cholangiocarcinoma and Gallbladder Cancer Studies、Pancreatic and Hepatic Oncology Research、Peptidase Inhibition and Analysis